579 related articles for article (PubMed ID: 22454039)
1. The endocannabinoids anandamide and virodhamine modulate the activity of the candidate cannabinoid receptor GPR55.
Sharir H; Console-Bram L; Mundy C; Popoff SN; Kapur A; Abood ME
J Neuroimmune Pharmacol; 2012 Dec; 7(4):856-65. PubMed ID: 22454039
[TBL] [Abstract][Full Text] [Related]
2. Anandamide inhibits FcεRI-dependent degranulation and cytokine synthesis in mast cells through CB
Cruz SL; Sánchez-Miranda E; Castillo-Arellano JI; Cervantes-Villagrana RD; Ibarra-Sánchez A; González-Espinosa C
Int Immunopharmacol; 2018 Nov; 64():298-307. PubMed ID: 30243065
[TBL] [Abstract][Full Text] [Related]
3. The orphan receptor GPR55 is a novel cannabinoid receptor.
Ryberg E; Larsson N; Sjögren S; Hjorth S; Hermansson NO; Leonova J; Elebring T; Nilsson K; Drmota T; Greasley PJ
Br J Pharmacol; 2007 Dec; 152(7):1092-101. PubMed ID: 17876302
[TBL] [Abstract][Full Text] [Related]
4. A synthetic cannabinoid, CP55940, inhibits lipopolysaccharide-induced cytokine mRNA expression in a cannabinoid receptor-independent mechanism in rat cerebellar granule cells.
Chiba T; Ueno S; Obara Y; Nakahata N
J Pharm Pharmacol; 2011 May; 63(5):636-47. PubMed ID: 21492165
[TBL] [Abstract][Full Text] [Related]
5. The molecular basis for neuroimmune receptor signaling.
Rogers TJ
J Neuroimmune Pharmacol; 2012 Dec; 7(4):722-4. PubMed ID: 22935971
[TBL] [Abstract][Full Text] [Related]
6. Role of pre-junctional CB1, but not CB2 , TRPV1 or GPR55 receptors in anandamide-induced inhibition of the vasodepressor sensory CGRPergic outflow in pithed rats.
Marichal-Cancino BA; Altamirano-Espinoza AH; Manrique-Maldonado G; MaassenVanDenBrink A; Villalón CM
Basic Clin Pharmacol Toxicol; 2014 Mar; 114(3):240-7. PubMed ID: 24118786
[TBL] [Abstract][Full Text] [Related]
7. Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor.
Porter AC; Sauer JM; Knierman MD; Becker GW; Berna MJ; Bao J; Nomikos GG; Carter P; Bymaster FP; Leese AB; Felder CC
J Pharmacol Exp Ther; 2002 Jun; 301(3):1020-4. PubMed ID: 12023533
[TBL] [Abstract][Full Text] [Related]
8. Atypical responsiveness of the orphan receptor GPR55 to cannabinoid ligands.
Kapur A; Zhao P; Sharir H; Bai Y; Caron MG; Barak LS; Abood ME
J Biol Chem; 2009 Oct; 284(43):29817-27. PubMed ID: 19723626
[TBL] [Abstract][Full Text] [Related]
9. Endocannabinoids selectively enhance sweet taste.
Yoshida R; Ohkuri T; Jyotaki M; Yasuo T; Horio N; Yasumatsu K; Sanematsu K; Shigemura N; Yamamoto T; Margolskee RF; Ninomiya Y
Proc Natl Acad Sci U S A; 2010 Jan; 107(2):935-9. PubMed ID: 20080779
[TBL] [Abstract][Full Text] [Related]
10. Is GPR55 an anandamide receptor?
Brown AJ; Robin Hiley C
Vitam Horm; 2009; 81():111-37. PubMed ID: 19647110
[TBL] [Abstract][Full Text] [Related]
11. Type 1 cannabinoid receptor ligands display functional selectivity in a cell culture model of striatal medium spiny projection neurons.
Laprairie RB; Bagher AM; Kelly ME; Dupré DJ; Denovan-Wright EM
J Biol Chem; 2014 Sep; 289(36):24845-62. PubMed ID: 25037227
[TBL] [Abstract][Full Text] [Related]
12. Cannabinoids and bone: endocannabinoids modulate human osteoclast function in vitro.
Whyte LS; Ford L; Ridge SA; Cameron GA; Rogers MJ; Ross RA
Br J Pharmacol; 2012 Apr; 165(8):2584-97. PubMed ID: 21649637
[TBL] [Abstract][Full Text] [Related]
13. Ligand activation of cannabinoid receptors attenuates hypertrophy of neonatal rat cardiomyocytes.
Lu Y; Akinwumi BC; Shao Z; Anderson HD
J Cardiovasc Pharmacol; 2014 Nov; 64(5):420-30. PubMed ID: 24979612
[TBL] [Abstract][Full Text] [Related]
14. The major endocannabinoid anandamide (AEA) induces apoptosis of human granulosa cells.
Costa L; Moreia-Pinto B; Felgueira E; Ribeiro A; Rebelo I; Fonseca BM
Prostaglandins Leukot Essent Fatty Acids; 2021 Aug; 171():102311. PubMed ID: 34126378
[TBL] [Abstract][Full Text] [Related]
15. Anandamide exerts its antiproliferative actions on cholangiocarcinoma by activation of the GPR55 receptor.
Huang L; Ramirez JC; Frampton GA; Golden LE; Quinn MA; Pae HY; Horvat D; Liang LJ; DeMorrow S
Lab Invest; 2011 Jul; 91(7):1007-17. PubMed ID: 21464819
[TBL] [Abstract][Full Text] [Related]
16. The endocannabinoid anandamide causes endothelium-dependent vasorelaxation in human mesenteric arteries.
Stanley CP; Hind WH; Tufarelli C; O'Sullivan SE
Pharmacol Res; 2016 Nov; 113(Pt A):356-363. PubMed ID: 27633407
[TBL] [Abstract][Full Text] [Related]
17. Anandamide inhibits transport-related oxygen consumption in the loop of Henle by activating CB1 receptors.
Silva GB; Atchison DK; Juncos LI; García NH
Am J Physiol Renal Physiol; 2013 Feb; 304(4):F376-81. PubMed ID: 23220721
[TBL] [Abstract][Full Text] [Related]
18. Endocannabinoids and Their Pharmacological Actions.
Pertwee RG
Handb Exp Pharmacol; 2015; 231():1-37. PubMed ID: 26408156
[TBL] [Abstract][Full Text] [Related]
19. Characterization of anandamide-stimulated cannabinoid receptor signaling in human ULTR myometrial smooth muscle cells.
Brighton PJ; McDonald J; Taylor AH; Challiss RA; Lambert DG; Konje JC; Willets JM
Mol Endocrinol; 2009 Sep; 23(9):1415-27. PubMed ID: 19477951
[TBL] [Abstract][Full Text] [Related]
20. CB1 cannabinoid receptor-mediated anandamide signaling mechanisms of the inferior colliculus modulate the haloperidol-induced catalepsy.
Medeiros P; de Freitas RL; Silva MO; Coimbra NC; Melo-Thomas L
Neuroscience; 2016 Nov; 337():17-26. PubMed ID: 27595886
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
